CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure

Pharmacogenetics and Genomics

Volumn 17, Issue 2, 2007, Pages 93-101

  Sistonen, Johanna ^a   Sajantila, Antti ^a   Lao, Oscar ^b   Corander, Jukka ^a   Barbujani, Guido ^c   Fuselli, Silvia ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

CYP2D6; Genetic variation; Genotyping; Polymorphism

Indexed keywords

CYTOCHROME P450 2D6; MICROSATELLITE DNA;

AFRICA; ARTICLE; AUTOSOME; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC VARIABILITY; GENOME; GENOTYPE; HAPLOTYPE; HUMAN; MEDICAL INFORMATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; POPULATION DISTRIBUTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; WESTERN HEMISPHERE;

ANALYSIS OF VARIANCE; CHROMOSOMES, HUMAN, PAIR 22; CLUSTER ANALYSIS; CYTOCHROME P-450 CYP2D6; GENE FREQUENCY; GENETICS, POPULATION; GEOGRAPHY; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; PHENOTYPE; VARIATION (GENETICS);

EID: 33847031732     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000239974.69464.f2     Document Type: Article

References (51)

1. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5:6-13.
2. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3:229-243.
3. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003; 348:1170-1175.
4. Cooper RS, Kaufman JS,Ward R. Race and genomics. N Engl J Med 2003; 348:1166-1170.
5. Kittles RA, Weiss KM. Race, ancestry, and genes: implications for defining disease risk. Annu Rev Genomics Hum Genet 2003; 4:33-67.
6. Jorde LB,Wooding SP. Genetic variation, classification and 'race'. Nat Genet 2004; 36:S28-S33.
7. Tishkoff SA, Kidd KK. Implications of biogeography of human populations for 'race' and medicine. Nat Genet 2004; 36:S21-S27.
8. Barbujani G. Human races: classifying people vs. understanding diversity. Curr Genom 2005; 6:215-226.
9. Romualdi C, Balding D, Nasidze IS, Risch G, Robichaux M, Sherry ST, et al. Patterns of human diversity, within and among continents, inferred from biallelic DNA polymorphisms. Genome Res 2002; 12:602-612.
10. Serre D, Paabo S. Evidence for gradients of human genetic diversity within and among continents. Genome Res 2004; 14:1679-1685.
11. Rosenberg NA, Pritchard JK,Weber JL, Cann HM, Kidd KK, Zhivotovsky LA, et al. Genetic structure of human populations. Science 2002; 298:2381-2385.
12. Bamshad MJ, Wooding S, Watkins WS, Ostler CT, Batzer MA, Jorde LB. Human population genetic structure and inference of group membership. Am J Hum Genet 2003; 72:578-589.
13. Tang H, Quertermous T, Rodriguez B, Kardia SL, Zhu X, Brown A, et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 2005; 76:268-275.
14. Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, Thomas MG, et al. Population genetic structure of variable drug response. Nat Genet 2001; 29:265-269.
15. Risch N, Burchard E, Ziv E, Tang H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol 2002; 3:comment 2007.
16. Tate SK, Goldstein DB. Will tomorrow's medicines work for everyone? Nat Genet 2004; 36:S34-S42.
17. Bloche MG. Race-based therapeutics. N Engl J Med 2004; 351:2035-2037.
18. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049-2057.
19. Rahemtulla T, Bhopal R. Pharmacogenetics and ethnically targeted therapies. BMJ 2005; 330:1036-1037.
20. Cann HM, de Toma C, Cazes L, Legrand MF, Morel V, Piouffre L, et al. A human genome diversity cell line panel. Science 2002; 296:261-262.
21. Sistonen J, Fuselli S, Levo A, Sajantila A. CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem 2005; 51:1291-1295.
22. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
23. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-1169.
24. Lewontin RC. The interaction of selection and linkage. I. General considerations: heterotic models. Genetics 1964; 49:49-67.
25. Hill WG, Robertson A. Linkage disequilibrium in finite populations. Theor Appl Genet 1968; 38:226-231.
26. Goddard KA, Hopkins PJ, Hall JM, Witte JS. Linkage disequilibrium and allele-frequency distributions for 114 single-nucleotide polymorphisms in five populations. Am J Hum Genet 2000; 66:216-234.
27. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R. DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 2003; 19:2496-2497.
28. Clement M, Posada D, Crandall KA. TCS: a computer program to estimate gene genealogies. Mol Ecol 2000; 9:1657-1659.
29. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:23-37.
30. Excoffier L, Smouse PE, Quattro JM. Analysis of molecular variance inferred from metric distances among DNA haplotypes: application to human mitochondrial DNA restriction data. Genetics 1992; 131:479-491.
31. Schneider S, Roessli D, Excoffier L. Arlequin, v 2.000: a software for population genetics data analysis. Geneva: Genetics and Biometry Laboratory, University of Geneva; 2000.
32. Rosenberg MS. PASSAGE: Pattern analysis, spatial statistics and geographic exegesis. Version 1.0. Tempe, AZ: Department of Biology, Arizona State University; 2001.
33. Ramachandran S, Deshpande O, Roseman CC, Rosenberg NA, Feldman MW, Cavalli-Sforza LL. Support from the relationship of genetic and geographic distance in human populations for a serial founder effect originating in Africa. Proc Natl Acad Sci USA 2005; 102:15942-15947.
34. Mantel N. The detection of disease clustering and a generalized regression approach. Cancer Res 1967; 27:209-220.
35. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278:441-446.
36. McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7:187-191.
37. Fuselli S, Dupanloup I, Frigato E, Cruciani F, Scozzari R, Moral P, et al. Molecular diversity at the CYP2D6 locus in the Mediterranean region. Eur J Hum Genet 2004; 12:916-924.
38. Barbujani G, Magagni A, Minch E, Cavalli-Sforza LL. An apportionment of human DNA diversity. Proc Natl Acad Sci USA 1997; 94:4516-4519.
39. Jorde LB, Watkins WS, Bamshad MJ, Dixon ME, Ricker CE, Seielstad MT, et al. The distribution of human genetic diversity: a comparison of mitochondrial, autosomal, and Y-chromosome data. Am J Hum Genet 2000; 66:979-988.
40. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296:2225-2229.
41. Tishkoff SA, Verrelli BC. Role of evolutionary history on haplotype block structure in the human genome: implications for disease mapping. Curr Opin Genet Dev 2003; 13:569-575.
42. Cavalli-Sforza LL, Menozzi P, Piazza A. The history and geography of human genes. Princeton, New Jersey: Princeton University Press; 1994.
43. Tishkoff SA, Goldman A, Calafell F, Speed WC, Deinard AS, Bonne-Tamir B, et al. A global haplotype analysis of the myotonic dystrophy locus: implications for the evolution of modern humans and for the origin of myotonic dystrophy mutations. Am J Hum Genet 1998; 62:1389-1402.
44. Corander J, Waldmann P, Sillanpaa MJ. Bayesian analysis of genetic differentiation between populations. Genetics 2003; 163:367-374.
45. Corander J, Waldmann P, Marttinen P, Sillanpaa MJ. BAPS 2: enhanced possibilities for the analysis of genetic population structure. Bioinformatics 2004; 20:2363-2369.
46. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 2000; 10:27-34.
47. Koski A, Ojanperä I, Vuori E, Sistonen J, Sajantila A. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am J Foren Med Path in press.
48. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351:2827-2831.
49. Suarez-Kurtz G. Pharmacogenomics in admixed populations. Trends Pharmacol Sci 2005; 26:196-201.
50. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-537.
51. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429:464-468.